CTLA4 and neoplasm: In NSCLC, Paulsen et al. demonstrated that tumor-cell expressed CTLA-4 in metastatic lymph nodes was associated with poorer survival, but stromal CTLA-4 expression was associated with improved LUSC disease-specific survival [121].